Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever

Summary

Establish the safety and efficacy of 3 months treatment with canakinumab in patients with colchicine resistant Familial Mediterranean Fever.

Timeline

Start

2010-04

Primary completion

2011-08

Completion

2011-08

Publications

• Gul A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015 Sep 4;17(1):243. doi: 10.1186/s13075-015-0765-4.

Drugs

Indications